ea0084op-07-36 | Oral Session 7: Thyroid Cancer Basic | ETA2022
Tiedje Vera
, Qin Tianyue
, Im Soo-Yeon
, P Krishnamoorthy Gnana
, A. Knauf Jeffrey
, A. Fagin James
Objectives: BRAFV600E- anaplastic thyroid cancers (ATCs) show remarkable responses to dabrafenib and trametinib (dab/tram) an effect that may be in part immune-mediated. Murine BRAFV600E-ATCs regress upon BRAF inhibition. We find that recurrences are frequent and associated with loss of Mhc class II (MhcII) expression. Our goal was to investigate the mechanisms of loss of antigen presentation by tumor cells and whether this contributes to disease recurren...